期刊
CARCINOGENESIS
卷 33, 期 9, 页码 1707-1716出版社
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgs207
关键词
-
类别
资金
- Fundacio Marato de TV3: Marato [TV3 04/050510]
- Fondo de Investigaciones Sanitarias [PI05/1776, PS09/00334, PI11/00525]
- Fundacion Mutua Madrilena [FMMIV 2006/169]
- Fundacion Salud
- AGAUR [SGR1437]
- ISCIII CIBER-BBN [CB06/01/1031]
- Red Nacional de Biobancos Hospitalarios [RD09/0076/00081]
- Ramon Mangues [FIS98/3197]
- Matilde Parreno [FIS01/3085]
- Marta Tellez-Gabriel [2009/FI/B/00431]
The purpose of this study was to identify molecular markers associated with tumor recurrence and survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). We studied the expression profile of 63 pre-treatment tumor biopsies obtained from locally advanced HNSCCs treated with standard treatments. Cluster analysis identified three tumor subtypes associated with significant differences in local recurrence-free survival (LRFS) (P < 0.001), progression free-survival (PFS) (P < 0.009) and overall survival (OS) (P < 0.004). Tumor subtype 1, associated with short LRFS, PFS and OS, showed features of epithelialmesenchymal transition and undifferentiation. It also overexpressed genes involved in cell adhesion, NF-B and integrin signalling. Tumor subtype 3, associated with longer LRFS, PFS and OS, showed a high degree of differentiation and overexpressed genes located in chromosomal regions 19q13 and 1q21. Tumor subtype 2, which had an intermediate clinical outcome between subtype 1 and subtype 3, overexpressed genes involved in branching morphogenesis. Finally, we validated the association between gene cluster classification and patient survival using Gene Set Enrichment Analysis and two HNSCC data sets obtained from two independent patient cohorts. In conclusion, we generated a gene prognostic signature associated with survival in locally advanced patients using the expression profile of the pre-treatment tumor biopsy. Independent prospective studies would be necessary to assess if the proposed survival signature could help to guide clinical management of HNSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据